@article{article, title = {{Dupilumab safety and efficacy in a phase III open-label extension trial in children 6鈥�11 years of age with severe atopic dermatitis}},
publisher = {{Springer Science and Business Media LLC}},
url = {{https://eprints.whiterose.ac.uk/id/eprint/204730 }},
year = {{2023}},
month = {{9}},
author = {{Cork MJ and Tha莽i D and Eichenfield LF and Arkwright PD and Chen Z and Thomas RB and Kosloski MP and Dubost-Brama A and Prescilla R and Bansal A and Levit NA}},
doi = {{10.1007/s13555-023-01016-9}},
volume = {{13}},
journal = {{Dermatology and Therapy}},
pages = {{2697-2719}},
note = {{Accessed on 2025/01/07}}}